Filing Overview
Nanobiotix S.A. filed a Form 6-K for September 2026. The report was submitted on September 24, 2026, under the foreign private issuer reporting requirements of the Securities Exchange Act of 1934.
Business Context and Reporting Period
The filing identifies Nanobiotix S.A., headquartered in Paris, France, and confirms that the company files annual reports on Form 20-F. The filing covers a press release issued September 24, 2026, designated as Exhibit 99.1.
Financial and Operating Metrics
The provided filing text does not include clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, cash balances, operating expenses, or other financial metrics.
Material Changes Versus Prior Period
The provided text does not describe any material changes versus a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not provide guidance, outlook commentary, risk disclosures, contingencies, or details of unusual items. The referenced Exhibit 99.1 press release is not included in the provided content.
Key Facts to Verify
- Obtain and review Exhibit 99.1, the press release dated September 24, 2026.
- Verify whether the press release contains financial results, clinical or business developments, financing information, or updated guidance.
- Confirm any material events, risks, or forward-looking statements described in the omitted exhibit.
- Note that the filing was signed by Bart Van Rhijn, Chief Financial Officer, on September 24, 2026.